Related Experiment Video

Updated: Dec 14, 2025

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.1K

Development of CD40L-modified tumor small extracellular vesicles for effective induction of antitumor immune response

Wen Liu1, Yuki Takahashi1, Masaki Morishita2

  • 1Department of Biopharmaceutics & Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, 606-8501, Japan.

Nanomedicine (London, England)
|July 16, 2020
PubMed

Insights

Modifying tumor-derived extracellular vesicles (TEVs) with CD40 ligand (CD40L) enhances their ability to activate dendritic cells (DCs). This improved DC activation facilitates efficient tumor antigen presentation for potential cancer vaccines.

Area of Science:

  • Immunology
  • Nanotechnology
  • Oncology

Background:

  • Tumor-derived small extracellular vesicles (TEVs) contain tumor antigens and are investigated for cancer immunotherapy.
  • Key challenges in TEV therapy include efficient delivery of tumor antigens to antigen-presenting cells (APCs), particularly dendritic cells (DCs), and subsequent DC activation.

Purpose of the Study:

  • To enhance the immunogenicity of TEVs for cancer vaccination.
  • To improve the uptake and activation of dendritic cells (DCs) by TEVs.
  • To facilitate the presentation of tumor antigens to T cells.

Main Methods:

  • Tumor-derived small extracellular vesicles (TEVs) were genetically modified to express CD40 ligand (CD40L).
  • The modified CD40L-TEVs were co-cultured with dendritic cells (DCs).
  • DC uptake, activation, and subsequent antigen presentation to T cells were analyzed.

Main Results:

  • CD40L-modified TEVs (CD40L-TEVs) demonstrated efficient uptake by dendritic cells (DCs).
  • CD40L-TEVs effectively activated DCs through CD40L-CD40 interactions.
  • DCs treated with CD40L-TEVs showed enhanced presentation of tumor antigens to T cells.

Conclusions:

  • Modification of TEVs with CD40L significantly improves their capacity to activate DCs.
  • CD40L-TEV technology holds promise for developing effective TEV-based cancer vaccines.
  • This approach enhances antigen presentation, a critical step in initiating anti-tumor immune responses.
Keywords:
CD40Lantigen presentationcancer therapydendritic cellssmall extracellular vesicles

More Related Videos

Generation of Human CD40-activated B cells13:27

Generation of Human CD40-activated B cells

Published on: October 16, 2009

15.6K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K